Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudyThomas J. Povsic, William A. Wargin, John H. Alexander et al.|European Heart Journal|2011Cited by 43
A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trialThomas J. Povsic, John H. Alexander, Mauricio G. Cohen et al.|American Heart Journal|2011Cited by 36
Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial DesignThomas J. Povsic, Richard C. Becker, Mauricio G. Cohen et al.|Journal of Thrombosis and Thrombolysis|2011Cited by 26
Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expressionDavid J. Stewart, W. P. Peters, William A. Wargin et al.|Journal of Clinical Oncology|2006Cited by 14